Industry News


Our news page will keep you informed of press releases and news articles on rapid and alternative microbiological method technologies and updates from technology suppliers.


Please click here to submit your news.

First Light Biosciences Announces Peer-Reviewed Publication on Rapid Diagnostic Tests

First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections today announced the publication of an article entitled, "A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples" in Nature Scientific Reports, a peer-reviewed, open access, multidisciplinary journal.

The paper presents results demonstrating the performance of First Light's rapid test for Clostridium difficile infection (CDI) using the company's novel MultiPath digital imaging technology. C. difficile, the bacterial pathogen that causes this devastating gastrointestinal infection, is responsible for about half of all hospital infections and about 29,000 deaths a year in the U.S. For these reasons C. difficile tops CDC's list of most urgent threats.

First Light's MultiPath CDI test uses ultra-sensitive single-molecule counting to detect the toxins that cause CDI. The newly published results demonstrate the test's potential to detect the disease-causing toxins at levels about 20-50 times lower than current toxin tests. On a set of 320 clinical stool samples, the MultiPath C. difficile toxin B test showed 97.0 percent clinical sensitivity, 98.3 percent specificity, and 98.2 percent accuracy compared to the FDA gold standard test.

"We are pleased with the results of our C. difficile study," said David Macdonald, CEO of First Light Biosciences. "Currently, there are no tests for this toxin that are rapid, sensitive and specific. This peer-reviewed publication offers compelling evidence that the MultiPath test provides superior accuracy."

Abstract:

We describe a new rapid and accurate immunoassay-based technology capable of counting single target molecules using digital imaging without magnification. Using the technology, we developed a rapid test for Clostridium difficile toxin B, which is responsible for the pathology underlying potentially fatal C. difficile infections (CDI). There are currently no tests for CDI that are rapid, sensitive, and specific. The MultiPath C. difficile toxin B test images and counts complexes of target-specific magnetic and fluorescent particles that have been tethered together by toxin B molecules in minimally processed stool samples. The performance characteristics of the 30 minute test include a limit of detection of 45 pg/mL, dynamic range covering 4–5 orders of magnitude, and coefficient of variation of less than 10%. The MultiPath test detected all toxinotypes and ribotypes tested, including the one most commonly occurring in the US and EU; shows no cross reactivity with relevant bacterial species; and is robust to potential interferants commonly present in stool samples. On a training set of 320 clinical stool samples, the MultiPath C. difficile toxin B test showed 97.0% sensitivity (95% CI, 91.4–99.4%); 98.3% specificity (95% CI, 96.8–99.2%); and 98.2% accuracy (95% CI, 96.7–99.0%) compared to the cellular cytotoxicity neutralization assay (CCNA) reference method. Based on these compelling performance characteristics, we believe the MultiPath technology can address the lack of rapid, sensitive, specific, and easy-to-use diagnostic tests for C. difficile.

Post a Comment

Previous Post Next Post

Contact Form